Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2010 09:40 ET | Source: Oxigene, Inc.

OXiGENE Announces $7.5 Million Financing

SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer...
February 25, 2010 16:16 ET | Source: Oxigene, Inc.

OXiGENE Reports Fourth Quarter and Year-End 2009 Results

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
February 19, 2010 16:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Fourth Quarter and Fiscal 2009 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
February 11, 2010 10:43 ET | Source: Oxigene, Inc.

OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat...
February 04, 2010 09:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen

SOUTH SAN FRANCISCO, Calif., Feb. 4, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
December 07, 2009 09:51 ET | Source: Oxigene, Inc.

OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference

Greater Antileukemic Activity Shown with OXi4503 Alone or Combined with Bevacizumab than Bevacizumab Alone SOUTH SAN FRANCISCO, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)...
November 17, 2009 12:30 ET | Source: Oxigene, Inc.

OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference

Combination of ZYBRESTAT With Bevacizumab Appears Well-Tolerated; Fewer Patient Deaths in Treatment Arm SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)...
November 12, 2009 16:01 ET | Source: Oxigene, Inc.

OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer...
November 10, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer...
November 09, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Reports Third Quarter 2009 Financial Results

Upcoming Milestones Include Presentation of Key Randomized Data in Phase 2 Study of ZYBRESTAT in Patients With Non-small Cell Lung Cancer SOUTH SAN FRANCISCO, Calif., Nov. 9, 2009 (GLOBE NEWSWIRE)...